Juno Therapeutics
Recent Finacing
Series B
Recent Raise
$134M
Juno Therapeutics is a Seattle-based clinical-stage biotech that engineers CAR and high-affinity TCR T cells to reprogram lymphocytes against cell-surface and intracellular tumor antigens, including CD19 and solid tumor antigens.
